Blood Review Time

The review timing makes more sense when you connect it to Blood's position in the field. This is not a hyper-selective generalist brand trying to sort across many disciplines. It is the flagship hematology room, which is why the journal can move efficiently on scope while still being demanding about whether a paper truly matters across hematology.

Blood was up from 20.3 in 2023 to 23.1 in 2024 after the post-pandemic hematology normalization period. The practical takeaway is that the journal still holds a strong structural baseline as the field's main flagship rather than merely riding a temporary citation wave.

Three factors make Blood's timeline more predictable:

Lower desk rejection rate. At ~40-50%, Blood sends more papers to review than Nature (~80% desk rejection) or Cell (~70-80%). This means more papers get a chance at peer review, and the editorial triage is less of a bottleneck.

Well-defined reviewer community. Hematology is a specific specialty with a identifiable reviewer pool. The ASH membership directory gives editors a clear map of who reviews what. Reviewer recruitment that takes 3-4 weeks at interdisciplinary journals often takes 1-2 weeks at Blood.

Broad scope within one specialty. Blood publishes basic, clinical, and translational hematology. This means papers rarely get desk-rejected for "scope mismatch" the way they do at journals with narrower editorial identities. If the paper is hematology, the scope question is usually settled.

Blood editors specifically screen whether the manuscript changes practice or understanding across hematology rather than within one narrow malignant, coagulation, or immunology slice. That is the real difference between a smooth flagship review and a redirect conversation.

Blood reviewers evaluate the paper within the standards of their hematology subspecialty. The review criteria shift by paper type:

For basic hematology: Is the mechanism novel? Are the model systems appropriate? Does the finding advance understanding of blood cell biology or blood disease?

For clinical hematology: Is the evidence strong enough to inform treatment? Are the endpoints clinically meaningful? Is the patient population representative?

For translational work: Does the bench-to-bedside bridge hold? Is the human relevance supported by data, not just discussion?

Blood reviewers tend to be constructive. The ASH culture emphasizes improving papers rather than gatekeeping. Revision requests are usually reasonable and focused.

When Blood editors see hematology merit but the paper isn't quite at the flagship threshold, they offer a redirect to Blood Advances (IF ~7). This is the most common alternative outcome after desk rejection.

The redirect includes the editor's assessment and sometimes the initial reviewer comments. This speeds up the process at Blood Advances significantly. Many papers that end up in Blood Advances went through this route.

Taking the redirect is usually the right call. Blood Advances shares the ASH brand, the same reviewer community, and reaches the same hematology audience.

SciRev data for Blood are sparse, but the small current set points to immediate decisions measured in days and first review rounds around four weeks. That is directionally consistent with Blood's reputation for quick specialty-specific handling once the paper is clearly in range.

Blood's timeline only helps if it changes what you do next. In practice, the useful question is whether the manuscript is strong enough for the flagship ASH route or whether the same hematology audience would be reached faster through a different journal in the cluster. The timing profile matters because Blood is not slow in a generic way. It is usually slow for papers that trigger real disease-model, mechanism, or clinical-translation scrutiny.

That is why authors should read the week count together with the journal-choice question. If the paper is clearly hematology-first and broad enough for the main Blood readership, a 6-10 week first-decision window is usually worth tolerating. If the editorial case is thinner, the same timeline may just be delaying an outcome that a more realistic target would have clarified sooner.

• Blood submission guide
• Blood submission process
• Blood impact factor
• Blood acceptance rate
• How to avoid desk rejection at Blood
• Is Blood a good journal?

In our pre-submission review work on Blood-targeted manuscripts, the files that slow down are usually not the ones with weak methods. They are the ones where the hematology consequence is still narrower than the journal's audience.

The paper is technically hematology-adjacent rather than hematology-centered. We see strong studies using blood cells, blood cancers, or coagulation systems as the model but still reading primarily as immunology, oncology, or cell biology papers. Blood moves fastest when the hematology logic is the core story, not an after-the-fact frame.

The clinical or translational implication is still too local. A result can matter deeply for one disease slice and still be too narrow for the flagship journal. Editors and reviewers here look for work that hematologists outside the exact niche will still recognize as important.

The manuscript has evidence, but not yet a field-wide takeaway. We see slower reviews when the study is solid but the reader still has to infer why this changes how hematology should think, diagnose, stratify, or manage. Blood is broad inside one specialty, which means the takeaway has to travel.

We see the cleanest outcomes when the manuscript can explain, in one sentence, what a hematologist outside the immediate niche should now understand differently. That is often the decisive step between a smooth flagship review and a redirect conversation.

Published timelines are medians that can mask real variation. Desk rejections (often 1-3 weeks) skew the median down, making the number shorter than what reviewed papers actually experience. Seasonal effects (December submissions sit longer, September backlogs) and field-specific reviewer availability also affect your specific wait time. The timeline does not include acceptance-to-publication time.

A Blood desk-rejection risk check scores fit against the journal's editorial bar.